LeMaitre Vascular Inc is a provider of medical devices and human tissue cryopreservation services mainly used in the treatment of peripheral vascular disease, end-stage renal disease, and cardiovascular disease... Show more
The Aroon Indicator for LMAT entered a downward trend on September 04, 2026. Tickeron's A.I.dvisor identified a pattern where the AroonDown red line was above 70 while the AroonUp green line was below 30 for three straight days. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options. A.I.dvisor looked at 122 similar instances where the Aroon Indicator formed such a pattern. In 71 of the 122 cases the stock moved lower. This puts the odds of a downward move at 58%.
The 10-day moving average for LMAT crossed bearishly below the 50-day moving average on August 07, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 8 of 16 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 50%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where LMAT declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 55%.
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where LMAT's RSI Indicator exited the oversold zone, 14 of 20 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 70%.
The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.
The Momentum Indicator moved above the 0 level on September 11, 2026. You may want to consider a long position or call options on LMAT as a result. In 78 of 104 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 75%.
The Moving Average Convergence Divergence (MACD) for LMAT just turned positive on August 28, 2026. Looking at past instances where LMAT's MACD turned positive, the stock continued to rise in 40 of 51 cases over the following month. The odds of a continued upward trend are 78%.
Following a +1.79% 3-day Advance, the price is estimated to grow further. Considering data from situations where LMAT advanced for three days, in 231 of 341 cases, the price rose further within the following month. The odds of a continued upward trend are 68%.
LMAT may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Tickeron Valuation Rating of 15 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.384) is normal, around the industry mean (4.965). P/E Ratio (28.178) is within average values for comparable stocks, (142.488). Projected Growth (PEG Ratio) (2.132) is also within normal values, averaging (3.236). Dividend Yield (0.012) settles around the average of (0.015) among similar stocks. P/S Ratio (7.289) is also within normal values, averaging (74.759).
The Tickeron SMR rating for this company is 52 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 57 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 96, placing this stock slightly better than average.
The Tickeron Price Growth Rating for this company is 73 (best 1 - 100 worst), indicating slightly worse than average price growth. LMAT’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 85 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
a manufacturer of vascular devices for vascular surgeons
Industry PharmaceuticalsOther